PT2252284E - COMPOSIÇÕES FARMACjUTICAS DE ENTACAPONE, LEVODOPA E CARBIDOPA COM BIODISPONIBILIDADE MELHORADA - Google Patents
COMPOSIÇÕES FARMACjUTICAS DE ENTACAPONE, LEVODOPA E CARBIDOPA COM BIODISPONIBILIDADE MELHORADA Download PDFInfo
- Publication number
- PT2252284E PT2252284E PT09709056T PT09709056T PT2252284E PT 2252284 E PT2252284 E PT 2252284E PT 09709056 T PT09709056 T PT 09709056T PT 09709056 T PT09709056 T PT 09709056T PT 2252284 E PT2252284 E PT 2252284E
- Authority
- PT
- Portugal
- Prior art keywords
- entacapone
- levodopa
- carbidopa
- pharmaceutical compositions
- improved bioavailability
- Prior art date
Links
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical group CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 title abstract 4
- 229960003337 entacapone Drugs 0.000 title abstract 4
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 150000005846 sugar alcohols Chemical class 0.000 abstract 2
- OTVUCEMFRGJEMR-FTXVUGNJSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(e)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethylprop-2-enamide;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1.CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 OTVUCEMFRGJEMR-FTXVUGNJSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN262MU2008 | 2008-02-06 | ||
| IN263MU2008 | 2008-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2252284E true PT2252284E (pt) | 2011-08-23 |
Family
ID=40626854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT09709056T PT2252284E (pt) | 2008-02-06 | 2009-02-06 | COMPOSIÇÕES FARMACjUTICAS DE ENTACAPONE, LEVODOPA E CARBIDOPA COM BIODISPONIBILIDADE MELHORADA |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8709485B2 (pt) |
| EP (1) | EP2252284B1 (pt) |
| JP (1) | JP5466179B2 (pt) |
| KR (1) | KR101444979B1 (pt) |
| CN (1) | CN101939003A (pt) |
| AT (1) | ATE510537T1 (pt) |
| AU (1) | AU2009211028B2 (pt) |
| BR (1) | BRPI0908052A2 (pt) |
| CA (1) | CA2714112C (pt) |
| MX (1) | MX2010008711A (pt) |
| NZ (1) | NZ587168A (pt) |
| PL (1) | PL2252284T3 (pt) |
| PT (1) | PT2252284E (pt) |
| RU (1) | RU2485947C2 (pt) |
| WO (1) | WO2009098661A1 (pt) |
| ZA (1) | ZA201005615B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101667762B1 (ko) * | 2008-08-22 | 2016-10-20 | 욱크하르트 리미티드 | 엔타카폰 또는 이의 염의 서방형 약학 조성물 |
| CA2735050C (en) * | 2008-08-22 | 2016-07-26 | Wockhardt Research Centre | Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof |
| TR200806646A2 (tr) * | 2008-09-03 | 2009-06-22 | Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. | Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar |
| JP5718937B2 (ja) * | 2009-12-25 | 2015-05-13 | イノファーマックス インコーポレイテッド | パーキンソン病を治療するための医薬組成物及びその調製方法 |
| CA2833443C (en) * | 2011-04-26 | 2017-11-07 | Innopharmax, Inc. | A composition of entacapone |
| TR201204839A2 (tr) * | 2012-04-25 | 2012-12-21 | Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. | Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu. |
| WO2014151742A1 (en) * | 2013-03-15 | 2014-09-25 | Mylan, Inc. | Formulation containing carbidopa, levodopa, and entacapone |
| ES2836325T3 (es) * | 2014-03-13 | 2021-06-24 | Neuroderm Ltd | Composiciones del inhibidor de la dopa descarboxilasa |
| DK3188725T3 (da) | 2014-09-04 | 2021-01-18 | Lobsor Pharmaceuticals Ab | Farmaceutiske sammensætninger omfattende levodopa, en dopamindecarboxylaseinhibitor og en comt-inhibitor og fremgangsmåde til indgivelse deraf |
| JP6567049B2 (ja) | 2014-10-21 | 2019-08-28 | アッヴィ・インコーポレイテッド | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 |
| WO2017039525A1 (en) * | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| CN106880607A (zh) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | 一种含有瑞戈非尼的口腔崩解片及其制备方法 |
| WO2018011181A1 (en) | 2016-07-11 | 2018-01-18 | Contera Pharma Aps | Pulsatile drug delivery system for treating morning akinesia |
| ES2895054T3 (es) * | 2016-08-18 | 2022-02-17 | Ilko Ilac Sanayi Ve Ticaret Anonim Sirketi | Fórmula de comprimido antiparkinson con perfil de disolución mejorado |
| CN106236720A (zh) * | 2016-08-29 | 2016-12-21 | 海南通用康力制药有限公司 | 一种恩他卡朋的药物组合物及其制备方法 |
| IL277553B1 (en) | 2018-03-23 | 2024-07-01 | Lobsor Pharmaceuticals Ab | Preparations for the treatment of neurodegenerative diseases by continuous administration |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
| EP0437098A3 (en) * | 1990-01-11 | 1991-09-18 | Warner-Lambert Company | Compressed confectionery tablets with at least two phases and sequential flavour delivery system |
| US6599530B2 (en) * | 1998-09-14 | 2003-07-29 | Orion Corporation | Oral compacted composition comprising catechol derivatives |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| DK1896006T3 (da) * | 2005-06-08 | 2009-12-07 | Orion Corp | Fremstillingmetode for entacapon-holdige granuler til orale doseringsformet |
| ZA200810834B (en) | 2006-05-31 | 2010-03-31 | Solvay Pharm Gmbh | Long term 24 hour intestinal administration of levodopa/carbidopa |
-
2009
- 2009-02-06 EP EP09709056A patent/EP2252284B1/en active Active
- 2009-02-06 US US12/865,745 patent/US8709485B2/en not_active Expired - Fee Related
- 2009-02-06 JP JP2010545596A patent/JP5466179B2/ja not_active Expired - Fee Related
- 2009-02-06 PT PT09709056T patent/PT2252284E/pt unknown
- 2009-02-06 AU AU2009211028A patent/AU2009211028B2/en not_active Ceased
- 2009-02-06 WO PCT/IB2009/050486 patent/WO2009098661A1/en active Application Filing
- 2009-02-06 MX MX2010008711A patent/MX2010008711A/es active IP Right Grant
- 2009-02-06 CN CN2009801045488A patent/CN101939003A/zh active Pending
- 2009-02-06 KR KR1020107019494A patent/KR101444979B1/ko not_active IP Right Cessation
- 2009-02-06 AT AT09709056T patent/ATE510537T1/de active
- 2009-02-06 CA CA2714112A patent/CA2714112C/en not_active Expired - Fee Related
- 2009-02-06 NZ NZ587168A patent/NZ587168A/en not_active IP Right Cessation
- 2009-02-06 BR BRPI0908052-0A patent/BRPI0908052A2/pt not_active IP Right Cessation
- 2009-02-06 PL PL09709056T patent/PL2252284T3/pl unknown
- 2009-02-06 RU RU2010136935/15A patent/RU2485947C2/ru not_active IP Right Cessation
-
2010
- 2010-08-05 ZA ZA2010/05615A patent/ZA201005615B/en unknown
-
2014
- 2014-03-01 US US14/194,685 patent/US9089485B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5466179B2 (ja) | 2014-04-09 |
| NZ587168A (en) | 2011-06-30 |
| PL2252284T3 (pl) | 2011-10-31 |
| US9089485B2 (en) | 2015-07-28 |
| KR101444979B1 (ko) | 2014-10-07 |
| EP2252284B1 (en) | 2011-05-25 |
| JP2011511061A (ja) | 2011-04-07 |
| RU2010136935A (ru) | 2012-03-20 |
| CA2714112A1 (en) | 2009-08-13 |
| AU2009211028A1 (en) | 2009-08-13 |
| CN101939003A (zh) | 2011-01-05 |
| US20140187644A1 (en) | 2014-07-03 |
| BRPI0908052A2 (pt) | 2015-08-11 |
| ATE510537T1 (de) | 2011-06-15 |
| US20110091558A1 (en) | 2011-04-21 |
| ZA201005615B (en) | 2011-10-26 |
| US8709485B2 (en) | 2014-04-29 |
| CA2714112C (en) | 2015-08-11 |
| KR20100117097A (ko) | 2010-11-02 |
| RU2485947C2 (ru) | 2013-06-27 |
| AU2009211028B2 (en) | 2013-12-05 |
| EP2252284A1 (en) | 2010-11-24 |
| MX2010008711A (es) | 2011-05-03 |
| WO2009098661A1 (en) | 2009-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201005615B (en) | Pharmaceutical compositions of entacapone,levodopa and carbidopa with improved bioavailability | |
| UA106877C2 (uk) | Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення | |
| PH12016500216B1 (en) | Stable pharmaceutical composition and methods of using same | |
| WO2008053297A3 (en) | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa | |
| WO2008128049A3 (en) | Tetrahydrobiopterin compositions and methods of measuring | |
| JO2973B1 (en) | Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol | |
| MY158504A (en) | Fatty acid niacin conjugates and their uses | |
| MY159630A (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof | |
| UA105229C2 (uk) | Фармацевтичний склад | |
| WO2007141392A3 (en) | Compositions comprising betulonic acid | |
| WO2008022974A3 (fr) | Composition antidiabetique contenant de l'acide chicorique et/ou l'un de ses metabolites | |
| MY159492A (en) | Solid pharmaceutical formulation with delayed release | |
| WO2012010977A8 (en) | Single daily dosage form for prevention and treatment of metabolic syndrome | |
| EP3228311A3 (en) | Pharmaceutical and nutraceutical compositions of abscisic acid | |
| WO2009120389A8 (en) | Oral and injectable formulations of tetracycline compounds | |
| UA102111C2 (uk) | Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі | |
| IL208151A0 (en) | Long-term stable pharmaceutical preparation having the active ingredient glycerol trinitrate | |
| JO3239B1 (ar) | تركيبات جالينية من مركبات عضوية | |
| WO2010029571A3 (en) | Modified release ramipril compositions and uses thereof | |
| MX2010008707A (es) | Composiciones farmaceuticas de entacapona comicronizada con alcoholes de azucar. | |
| WO2014006571A3 (en) | Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof | |
| TW200738703A (en) | 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
| WO2010028130A3 (en) | Antidepressant compounds | |
| WO2007120544A3 (en) | Compositions comprising pyruvate alkyl esters and uses thereof | |
| GR20100100508A (el) | Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια του υποθυρεοειδισμου |